Limits...
Retrospective analysis of genetic abnormalities and survival in 131 patients with multiple myeloma.

Liu N, Zhou H, Yang G, Geng C, Jian Y, Guo H, Chen W - Oncol Lett (2014)

Bottom Line: Patients with t(4;14) commonly exhibited lower levels of albumin and hemoglobin.The 1q21 gain and 17p13 deletion were also adverse prognostic factors for MM.These findings demonstrate that patients with two or more iFISH abnormalities, a gain of the 1q21 region or a 17p13 deletion were more likely to have a poor prognosis; however, bortezomib treatment improved the outcome for MM patients with unfavorable iFISH abnormalities.

View Article: PubMed Central - PubMed

Affiliation: Department of Hematology, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, P.R. China.

ABSTRACT

Genetic abnormalities in patients with multiple myeloma (MM) are important risk factors in terms of prognosis. In the present study, the prognostic value of several common MM genetic abnormalities was investigated. Interphase fluorescence in situ hybridization (iFISH) was used to detect genetic abnormalities, including 1q21 gain, t(4;14), t(11;14), t(14;16) and 17p13 deletion in 131 patients. A total of 46.6% patients were detected with one or more abnormalities using iFISH analysis. The 1q21 gain, t(4;14), t(11;14), t(14;16) and 17p13 deletion abnormalities were detected in 42.5, 6.9, 17.5, 0.8 and 10.7% of patients, respectively. Patients with t(4;14) commonly exhibited lower levels of albumin and hemoglobin. The progression-free survival (PFS) and overall survival times of iFISH-positive patients (particularly patients with two or more iFISH abnormalities) were significantly shorter than those of the patients without detectable abnormalities. The 1q21 gain and 17p13 deletion were also adverse prognostic factors for MM. Bortezomib-based therapies improved the PFS times in the patients with unfavorable iFISH abnormalities. These findings demonstrate that patients with two or more iFISH abnormalities, a gain of the 1q21 region or a 17p13 deletion were more likely to have a poor prognosis; however, bortezomib treatment improved the outcome for MM patients with unfavorable iFISH abnormalities.

No MeSH data available.


Related in: MedlinePlus

(A) Overall survival (OS) times of multiple myeloma (MM) patients according to fluorescence in situ hybridization (FISH) abnormalities. (B) Progression-free survival (PFS) times of MM patients according to FISH abnormalities. (C) PFS times of MM patients according to 1q21 gain. (D) OS times of MM patients according to 17p deletion.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4301547&req=5

f1-ol-09-02-0930: (A) Overall survival (OS) times of multiple myeloma (MM) patients according to fluorescence in situ hybridization (FISH) abnormalities. (B) Progression-free survival (PFS) times of MM patients according to FISH abnormalities. (C) PFS times of MM patients according to 1q21 gain. (D) OS times of MM patients according to 17p deletion.

Mentions: The prognostic impact of each iFISH abnormality on the PFS and OS times was analyzed. Patients with two or more iFISH abnormalities had significantly shorter OS and PFS times than patients with one or no abnormality (median OS time, 30.4 vs. 48.7 months vs. not reached (OS time>follow-up time), respectively; P=0.013; Fig. 1A; and median PFS time, 14.0 vs. 21.6 vs. 27.0 months, respectively; P=0.011; Fig. 1B). Significantly shorter PFS times were observed in the patients with 1q21 gain versus those without 1q21 gain (median PFS time, 14.0 months vs. not reached, respectively; P=0.042; Fig. 1C). The patients with the 17p13 deletion had a significantly poorer outcome compared with the patients without the 17p13 deletion, with a median OS time of 48.7 months versus not reached, respectively (P=0.026; Fig. 1D). The presence/absence of t(11;14) and t(4;14) were not associated with a statistically significant effect on the PFS or OS times. All data are summarized in Table III.


Retrospective analysis of genetic abnormalities and survival in 131 patients with multiple myeloma.

Liu N, Zhou H, Yang G, Geng C, Jian Y, Guo H, Chen W - Oncol Lett (2014)

(A) Overall survival (OS) times of multiple myeloma (MM) patients according to fluorescence in situ hybridization (FISH) abnormalities. (B) Progression-free survival (PFS) times of MM patients according to FISH abnormalities. (C) PFS times of MM patients according to 1q21 gain. (D) OS times of MM patients according to 17p deletion.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4301547&req=5

f1-ol-09-02-0930: (A) Overall survival (OS) times of multiple myeloma (MM) patients according to fluorescence in situ hybridization (FISH) abnormalities. (B) Progression-free survival (PFS) times of MM patients according to FISH abnormalities. (C) PFS times of MM patients according to 1q21 gain. (D) OS times of MM patients according to 17p deletion.
Mentions: The prognostic impact of each iFISH abnormality on the PFS and OS times was analyzed. Patients with two or more iFISH abnormalities had significantly shorter OS and PFS times than patients with one or no abnormality (median OS time, 30.4 vs. 48.7 months vs. not reached (OS time>follow-up time), respectively; P=0.013; Fig. 1A; and median PFS time, 14.0 vs. 21.6 vs. 27.0 months, respectively; P=0.011; Fig. 1B). Significantly shorter PFS times were observed in the patients with 1q21 gain versus those without 1q21 gain (median PFS time, 14.0 months vs. not reached, respectively; P=0.042; Fig. 1C). The patients with the 17p13 deletion had a significantly poorer outcome compared with the patients without the 17p13 deletion, with a median OS time of 48.7 months versus not reached, respectively (P=0.026; Fig. 1D). The presence/absence of t(11;14) and t(4;14) were not associated with a statistically significant effect on the PFS or OS times. All data are summarized in Table III.

Bottom Line: Patients with t(4;14) commonly exhibited lower levels of albumin and hemoglobin.The 1q21 gain and 17p13 deletion were also adverse prognostic factors for MM.These findings demonstrate that patients with two or more iFISH abnormalities, a gain of the 1q21 region or a 17p13 deletion were more likely to have a poor prognosis; however, bortezomib treatment improved the outcome for MM patients with unfavorable iFISH abnormalities.

View Article: PubMed Central - PubMed

Affiliation: Department of Hematology, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, P.R. China.

ABSTRACT

Genetic abnormalities in patients with multiple myeloma (MM) are important risk factors in terms of prognosis. In the present study, the prognostic value of several common MM genetic abnormalities was investigated. Interphase fluorescence in situ hybridization (iFISH) was used to detect genetic abnormalities, including 1q21 gain, t(4;14), t(11;14), t(14;16) and 17p13 deletion in 131 patients. A total of 46.6% patients were detected with one or more abnormalities using iFISH analysis. The 1q21 gain, t(4;14), t(11;14), t(14;16) and 17p13 deletion abnormalities were detected in 42.5, 6.9, 17.5, 0.8 and 10.7% of patients, respectively. Patients with t(4;14) commonly exhibited lower levels of albumin and hemoglobin. The progression-free survival (PFS) and overall survival times of iFISH-positive patients (particularly patients with two or more iFISH abnormalities) were significantly shorter than those of the patients without detectable abnormalities. The 1q21 gain and 17p13 deletion were also adverse prognostic factors for MM. Bortezomib-based therapies improved the PFS times in the patients with unfavorable iFISH abnormalities. These findings demonstrate that patients with two or more iFISH abnormalities, a gain of the 1q21 region or a 17p13 deletion were more likely to have a poor prognosis; however, bortezomib treatment improved the outcome for MM patients with unfavorable iFISH abnormalities.

No MeSH data available.


Related in: MedlinePlus